The Global Acetazolamide Market is Anticipated to Witness High Growth Owing to Increasing Prevalence of Glaucoma
![]() |
Acetazolamide Market |
Global acetazolamide market is
driven by increasing prevalence of glaucoma. Acetazolamide is a carbonic
anhydrase inhibitor drug primarily used for the treatment of glaucoma. It
reduces the amount of fluid in the eye by inhibiting the carbonic anhydrase
enzyme and lowering intraocular pressure. Acetazolamide comes in tablet,
capsule, and intravenous forms and is prescribed after the initial treatment
with eye drops fails to adequately lower pressure or if surgery is not a viable
option.
The Global
Acetazolamide Market Share was estimated to be US$ 303.03 Bn in 2024 and is anticipated to register a CAGR of 13% during the forecast period
of 2024 to 2030.
Key Takeaways
Key players operating in the
acetazolamide market are Merck KgaA, QIAGEN NV, Illumina Inc., Micronit BV,
PerkinElmer Inc., Thermo Fisher Scientific, Fluidigm Corporation, Bio-Rad
Laboratories Inc., Agilent Technologies Inc., Abbott Laboratories, Phalanx
Biotech Group, and Danaher Corporation (Cepheid), among others. Acetazolamide
being the only effective medication has led to increasing demand for the drug.
The key market players are focused on expansions, collaborations and new
product launches to enhance their global footprint and better serve the demand
from medical professionals and glaucoma patients globally.
Growing demand in market:
The growing prevalence of
glaucoma across the world is the major factor driving the growth of the global
acetazolamide market. As per the estimates of World Health Organization (WHO),
over 3 million people globally are blind due to glaucoma. It has been reported
that globally over 60 million people suffer from primary angle-closure glaucoma
with women being three times more affected than men.
Global expansion of market:
The increasing collaborations
between the key market players to expand geographical presence fuels the growth
of the acetazolamide market globally. The rising investments by the government
and private organizations in development of novel drugs for treatment of
glaucoma further support the market growth. Additionally, the growing awareness
regarding early glaucoma diagnosis supplements the increasing demand of
acetazolamide over the forecast period.
Market drivers:
One of the key drivers for the
acetazolamide market is increasing aging population worldwide. The condition is
more common in geriatric patients and the proportion of geriatric population is
rising rapidly globally. As per the United Nations’ World Population Ageing
report, the number of people aged 65 years or over is projected to grow from
703 million in 2019 to 1.5 billion in 2050. The rising geriatric populace
susceptible to developing glaucoma will augment the demand of acetazolamide
over coming years.
The global security environment
has significantly deteriorated in 2022 with the ongoing conflict in Ukraine
intensifying geopolitical tensions. This has impacted several industries
globally as supply chains have been disrupted due to sanctions imposed on Russia.
The acetazolamide market is also expected to be affected in the short to medium
term. Countries in Europe which earlier imported raw materials and
intermediates from Russia will now need to find new reliable suppliers. While
countries like India, China and South America can help plug supply gaps, it
will take time to establish long term supply contracts and stabilize prices.
Geopolitical risks will remain
elevated for the foreseeable future as major powers continue to spar over
trade, technology and strategic influence. The acetazolamide market will see
higher input costs and demand fluctuations owing to geopolitical developments
in key exporting and importing regions. Companies need to closely monitor
changes in trade policies and diversify their supplier networks across multiple
regions to reduce vulnerabilities from concentration risks. Stockpiling of
critical raw materials may also help mitigate shortages during times of
conflict or sanctions. Collaborations in research & development can further
aid in indigenization of technology and independence from politically unstable
regions.
In terms of value, North America
is currently the largest market for acetazolamide, estimated at over 35% share of
the global total. This is attributed to rising incidence of glaucoma and a
well-developed pharmaceutical sector in the US and Canada supported by
favorable reimbursement policies. However, going forward the Asia Pacific
region excluding Japan is poised to be the fastest growing regional market,
expected to expand at a CAGR of around 15% during the forecast period. Rapid
economic development, rising medical expenditures, growing geriatric population
base susceptible to ophthalmic conditions are driving demand growth in
countries like China and India.
Get More Insights Here
https://www.newsanalyticspro.com/acetazolamide-market-size-share-growth-outlook-2023/
Comments
Post a Comment